Track CTKB and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Create a free account to build watchlists, compare peers, and value any stock.
No credit card required
CTKB - Cytek Biosciences Inc (CTKB) has a revenue of $204.17M, up 0.5% over the past year and up 16.8% per year over the past five years.
Revenue TTM
$204.17M
5Y CAGR
16.76%
3Y CAGR
7.10%
Gross Margin
51.70%
| Year | Revenue | Change |
|---|---|---|
| 2025 | $201.49M | +0.52% |
| 2024 | $200.45M | +3.85% |
| 2023 | $193.01M | +17.67% |
| 2022 | $164.04M | +28.20% |
| 2021 | $127.95M | +37.82% |
| 2020 | $92.84M | - |
| Quarter | Revenue | Change |
|---|---|---|
| Q1 2026 | $44.13M | -28.98% |
| Q4 2025 | $62.14M | +18.83% |
| Q3 2025 | $52.29M | +14.67% |
| Q2 2025 | $45.60M | +10.00% |
| Q1 2025 | $41.46M | -27.87% |
| Q4 2024 | $57.48M | +11.60% |
| Q3 2024 | $51.50M | +10.47% |
| Q2 2024 | $46.62M | +3.92% |
| Q1 2024 | $44.86M | -22.96% |
| Q4 2023 | $58.23M | +21.32% |
| Q3 2023 | $48.00M | -3.41% |
| Q2 2023 | $49.69M | +33.99% |
| Q1 2023 | $37.09M | -23.27% |
| Q4 2022 | $48.34M | +19.42% |
| Q3 2022 | $40.48M | +0.79% |
| Q2 2022 | $40.16M | +14.53% |
| Q1 2022 | $35.06M | -9.85% |
| Q4 2021 | $38.89M | +13.14% |
| Q3 2021 | $34.38M | +13.05% |
| Q2 2021 | $30.41M | +25.28% |
| Q1 2021 | $24.27M | -20.73% |
| Q4 2020 | $30.62M | +22.01% |
| Q3 2020 | $25.10M | +31.15% |
| Q2 2020 | $19.14M | +6.38% |
| Q1 2020 | $17.99M | - |
Revenue — often called the top line — is the total amount a company earns from selling its products and services before any expenses are deducted. Consistent revenue growth is a core signal of expanding demand and a healthy business.